Group 1 - The 2025 version of the chikungunya treatment plan has been released, leading to a rise in companies like Lide Man and Rejing Bio, boosting the medical device sector [1] - The medical device ETF (562600) closed up by 0.67% [1] - The 11th batch of centralized procurement has been initiated, with the National Medical Insurance Administration announcing measures to alleviate low-price competition in the industry [1] Group 2 - The National Medical Products Administration released measures in early July to support the innovation and development of high-end medical devices [1] - There is a positive outlook for innovative drugs and devices due to clear policy support in regulation and payment, which is expected to accelerate the development of domestic high-end devices [1] - The medical device ETF (562500) has a brain-computer interface component of 22.72%, leading the market and is expected to benefit from the growing interest in brain-computer interfaces [1]

Group 1 - The core viewpoint of the news highlights a surge in virus prevention concept stocks, particularly in response to the release of the 2025 treatment plan for Chikungunya virus, which has led to significant stock price increases for several companies in the pharmaceutical sector [1][2] - Companies such as Lide Man and Lianhuan Pharmaceutical saw their stock prices rise by 20% and nearly 10% respectively, indicating strong market interest and potential investment opportunities in the sector [2] - The news also mentions that there is currently no available vaccine for the Chikungunya virus in China, which may drive demand for preventive measures and related pharmaceutical products [1] Group 2 - Specific stock performance data shows that Hotgen Biotech increased by over 9%, while Zhongsheng Pharmaceutical rose by over 7%, reflecting a broader trend of growth among virus prevention stocks [1][2] - The total market capitalization of Lide Man is reported at 4.597 billion, while Lianhuan Pharmaceutical stands at 5.538 billion, indicating substantial company valuations in the context of the current market dynamics [2] - Year-to-date performance shows that Hotgen Biotech has increased by 244.50%, suggesting a strong upward trend in investor confidence and market performance for this company [2]

Group 1 - The core viewpoint of the news highlights a significant rise in virus prevention stocks, particularly in response to the reported cases of Chikungunya fever in Foshan, Guangdong Province [1][2][3] - Notable stock performances include Zhifei Biological, which increased by 16.86%, and Watson Bio, which rose by 13.39%, among others [2] - The total market capitalization of Zhifei Biological is reported at 57.7 billion, while Watson Bio stands at 21 billion [2] Group 2 - As of July 22, Foshan has reported a total of 3,195 confirmed cases of Chikungunya fever, primarily concentrated in the Shunde District [2] - The World Health Organization has issued a warning regarding mosquito-borne diseases, urging countries to prepare for potential outbreaks [3]